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1002Objective: Up to 90% of embolic strokes that occur in patients with atrial fibrillation originate from the left
atrial appendage. Exclusion of the left atrial appendage during cardiac surgery may decrease the future risk
of stroke, especially in patients with atrial fibrillation or at high risk for developing atrial fibrillation. We report
the initial results of a multicenter Food and Drug Administration trial to assess the safety and efficacy of a novel
left atrial appendage exclusion clip.
Methods: Patients undergoing elective cardiac surgery via median sternotomy with atrial fibrillation or a Con-
gestive Heart Failure, Hypertension, Age> 75 Years, Diabetes Mellitus, Stroke score greater than 2 were
eligible for concomitant AtriClip (Atricure Inc, Westchester, Ohio) device insertion. Device insertion (35,
40, 45, and 50 mm) was performed at any point after sternotomy on or off cardiopulmonary bypass. Safety
was assessed at 30 days, and efficacy of left atrial appendage exclusion was assessed at operation (by transe-
sophageal echocardiography) and 3-month follow-up (by computed tomography angiography or transesopha-
geal echocardiography).
Results: A total of 71 patients (mean age, 73 years) undergoing open cardiac surgery at 7 US centers were
enrolled in the study. The left atrial appendage in 1 patient was too small and did not meet eligibility criteria;
the remaining 70 patients had successful placement of an AtriClip device. Intraprocedural successful left atrial
appendage exclusion was confirmed in 67 of 70 patients (95.7%). Although significant adverse events occurred
in 34 of 70 patients (48.6%), therewere no adverse events related to the device and no perioperativemortality. At
3-month follow-up, 1 patient died and 65 of 70 patients (92.9%) were available for assessment. Of the patients
who underwent imaging, 60 of 61 patients (98.4%) had successful left atrial appendage exclusion by computed
tomography angiography or transesophageal echocardiography imaging.
Conclusions: In this small study, safe and atraumatic exclusion of the left atrial appendage can be performed
during open cardiac surgery with the AtriClip device with greater than 95% success and appears to be durable
in the short term by imaging. Long-term studies are needed to evaluate the efficacy in the prevention of stroke.
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The Journal of Thoracic and Cardiovascular SurAtrial fibrillation (AF) is a well-known risk factor for
stroke, increasing the lifetime risk for a patient by up to
5-fold.1 There is evidence that up to 90% of embolic strokes
that occur in patients with AF originate from the left atrial
appendage (LAA).2 In addition, the LAA is thought to be
a driver for AF in a small group of patients with persistent
AF.3 It has been recommended that the LAA be excluded
or excised in patients undergoing surgical treatment for
AF or mitral valve surgery in an effort to decrease the future
risk of thromboembolism.4
Currently available surgical methods to isolate blood
flow to the LAA include (1) suture ligation, (2) excision
and suture closure, and (3) stapling exclusion with or with-
out excision. However, removal of the LAA is not inconse-
quential because these techniques are imperfect and
sometimes traumatic to the appendage. Moreover, when us-
ing techniques that do not remove the LAA, studies have
documented residual blood flow through the closure line
into the appendage during follow-up in up to one third of pa-
tients.5,6 It has been suggested that patients with persistentgery c November 2011
Abbreviations and Acronyms
AF ¼ atrial fibrillation
AE ¼ adverse event
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CHADS ¼ Congestive Heart Failure,
Hypertension, Age>75 years,
Diabetes Mellitus, Stroke
CTA ¼ computed tomography
angiography
EXCLUDE ¼ Exclusion of Left Atrial
Appendage with AtriClip
Exclusion Device in Patients
Undergoing Concomitant Cardiac
Surgery
FDA ¼ Food and Drug Administration
LAA ¼ left atrial appendage
TEE ¼ transesophageal echocardiography
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Dflow into the LAA have a greater likelihood of left atrial
thrombus.6 A number of catheter-based endocardial and
minimally invasive epicardial methods recently have been
developed to treat the LAA. Recent reports suggest mini-
mally invasive and percutaneous LAA closure as a stand-
alone treatment for AF.7,8
The AtriClip device (Atricure, West Chester, Ohio) is
placed epicardially at the base of the appendage in an effort
to exclude blood flow into the LAA. The Exclusion of Left
Atrial Appendage with AtriClip Exclusion Device in
Patients Undergoing Concomitant Cardiac Surgery (EX-
CLUDE) clinical trial is a nonrandomized, prospective
multicenter trial designed to assess the safety and efficacy
of this novel clip.MATERIALS AND METHODS
Patients
This study reports the results of the EXCLUDE trial (ClinicalTrials.gov
number, NCT00779857). All patients provided written informed consent.
Adult patients undergoing elective primary cardiac operations via median
sternotomy, including coronary artery bypass grafting (CABG), valve re-
pair or replacement, surgical Maze procedures (ablative or cut-and-sew),
or atrial septal defect repair, were evaluated. Patients with any of the
following criteria were eligible for enrollment and concomitant AtriClip
device insertion: AF, age greater than 65 years with hypertension, age
more than 75 years, previous stroke, or a Congestive Heart Failure, Hyper-
tension, Age > 75 Years, Diabetes Mellitus, Stroke (CHADS2) score
greater than 2 points (1 point for each risk factor, including presence of con-
gestive heart failure, hypertension, age  75 years, diabetes mellitus, or
previous stroke [2 points]). The CHADS2 score was designed to estimate
the risk of stroke in patients with non-rheumatic AF and is used to deter-
minewhich patients with AF should be maintained on warfarin.22 Pertinent
exclusion criteria included previous cardiac surgery, need for emergency
cardiac surgery, creatinine greater than 200 mmol/L, and steroid treatment.
Complete inclusion and exclusion criteria are shown in Table E1. InThe Journal of Thoracic and Caraddition, patients with evidence of LAA thrombus by intraoperative trans-
esophageal echocardiography (TEE) were excluded. A total of 71 patients
were enrolled at 7 centers in the United States (Figure 1). The first patient
was enrolled in October 2008, and the last patient was enrolled in June
2009. The last 12-month follow-up visit was in June 2010.
Device Placement
The AtriClip device is a clip made of 2 parallel rigid titanium tubes with
elastic nitinol springs covered with a knit-braided polyester sheath.11 At the
time of this study, a large first-generation deployment tool was used, which
has currently been replaced with a smaller applicator. Before sternotomy,
the LAA was assessed by intraoperative echocardiography to ensure no
evidence of intraatrial thrombus. After sternotomy, device insertion was
performed at any point during the operation before, during, or without car-
diopulmonary bypass and was based on surgeon preference. The base of the
LAAwasmeasured. Four different size clips were available (35, 40, 45, and
50 mm) based on the size of the LAA base as previously described.9-11 The
heart is rotated to the right such that the LAA is brought into view. The clip
is placed at the base of the appendage avoiding the circumflex and
pulmonary arteries. If the location of the clip is not satisfactory, the clip
can be repositioned before deployment. Once the clip is in optimal
position, it is closed and released from the deployment tool manually.
Repositioning once deployed is challenging and requires careful manual
opening of the clip and reinsertion on the deployment tool. Successful
LAA exclusion was assessed intraoperatively by TEE.
Safety and Efficacy End Points
The primary safety end point was device-related adverse events (AEs) at
30 days. The primary efficacy end point of successful LAA exclusion was
a composite of intraprocedural TEE exclusion of flow to the LAA and exclu-
sion assessed at 3-month follow-up by computed tomography angiography
(CTA). Patients who could not receive intravenous contrast for CTA because
of allergy or poor renal function underwent assessment by TEE. Efficacy of
appendage exclusion was adjudicated by an independent core laboratory.
Secondary end points included (1) device placement success defined by
the ability to successfully implant the device to the target location, (2) tech-
nical success defined by the ability to successfully implant an AtriClip de-
vice in a patient, (3) intraprocedural success defined by successful
exclusion of the LAA by visual assessment and TEE, and (4) 3-month suc-
cessful exclusion of the LAA as assessed by core laboratory review of the
CTA. Patients who were unable to undergo CTA because of renal insuffi-
ciency or contrast allergy were offered TEE at 3 months. These echocardio-
grams were assessed by individual sites. CTA and TEE have been reported
in the literature as imaging modalities to assess the LAA.23,24 The target
rate for the primary safety end point of device-related AEs was less than
10%. The target rate for the primary efficacy end point of LAA exclusion
was greater than 95%.
Statistical Analysis
Data from this study were tabulated using descriptive statistics. Continu-
ous variables are presented as means and standard deviations, as well as me-
dians and ranges. For categoric variables, relative frequencies are provided.
Statistical evaluations of the primary outcome measures were per-
formed using Bayesian analysis methods. Bayesian credible intervals
were used to illustrate the certainty with which the AE rates and efficacy
rates are estimated. This prospective study protocol used Bayesian analyses
for the primary safety and efficacy analyses and was reviewed by the Food
and Drug Administration (FDA) Center for Devices and Radiological
Health before study initiation and in accordance with the Center for De-
vices and Radiological Health’s ‘‘Guidance for the Use of Bayesian Statis-
tics in Medical Device Clinical Trials.’’ In the final analysis, the posterior
distribution of LAA exclusion success rate and serious device-related AE
rate are summarized graphically via histogram and with 1-sided 95%diovascular Surgery c Volume 142, Number 5 1003
FIGURE 1. Enrollment and follow-up scheme of patients enrolled in the EXCLUDE trial. f/u, Follow-up; CT, computed tomography; TEE, transeso-
phageal echocardiography.
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clusion success rate greater than 95% and Bayesian posterior probability of
serious device-related AE rate less than 10% are reported.
AEs were summarized on the basis of seriousness, causality and associ-
ation with the device, procedure, or comorbid condition. All AEs are sum-
marized through 6 months according to the outcome of independent
adjudication rather than as reported by the site.
Statistical analyses are produced using SAS Version 9.1 (SAS Institute
Inc, Cary, NC). Statistical evaluations were performed using a 2-sided
significance level of .05 unless otherwise specified.RESULTS
Patient Demographics and Baseline Information
A total of 71 patients were enrolled in the EXCLUDE
trial across 7 sites (1 patient withdrew consent; Figure 1).
Enrollment ranged from 2 patients (2.8%) at 1 site to 171004 The Journal of Thoracic and Cardiovascular Surpatients (23.9%) at each of 2 sites. Median enrollment
was 10 patients per site. The mean age for enrolled patients
was 73.3 years, and 67.6%were male (Table 1). The major-
ity of patients were white (97.2%) and in functional New
York Heart Association class II or III. The majority of
patients underwent CABG (77.5%), and approximately
40% underwent aortic valve replacement (AVR; Table 2).
In addition, approximately 35% of enrolled patients under-
went surgical Maze procedures. Twenty-six patients under-
went an isolated procedure including isolated CABG
(n ¼ 17 patients), AVR (n ¼ 6), or mitral valve operation
(n ¼ 3). The remaining 45 patients had 2 or more proce-
dures, most commonly CABG/AVR (n ¼ 14), CABG/
AVR/Maze (n ¼ 5), CABG/mitral repair (n ¼ 4). The
remaining patients had some combination of mitral valvegery c November 2011
TABLE 1. Baseline and demographic variables of patients enrolled in
the EXCLUDE study
Patient variable
Total
N ¼ 71
Baseline information
Age, y
Mean  SD 73.3  8.2
Median (range) 74.0 (48.0-87.0)
Gender [% (n/N)]
Male 67.6% (48/71)
Female 32.4% (23/71)
Ethnic group [% (n/N)]
White 97.2% (69/71)
Black 1.4% (1/71)
Hispanic 1.4% (1/71)
NYHA classification [% (n/N)]
I 12.7% (9/71)
II 45.1% (32/71)
III 40.8% (29/71)
IV 0.0% (0/71)
Not done 1.4% (1/71)
Antiarrhythmic medication
Class I A 0.0% (0/71)
Class I B 0.0% (0/71)
Class I C 4.2% (3/71)
Class III 5.6% (4/71)
Cardiac and related medication
ACE inhibitors 46.5% (33/71)
Anticoagulants/antiplatelet 78.9% (56/71)
Beta-blockers 52.1% (37/71)
Caþchannel blockers 22.5% (16/71)
Diuretics 63.4% (45/71)
Intraoperative TEE assessment
available [%(n/N)] [%(n/N)]
98.6% (70/71)
EF (%)
Mean  SD (N) 52.3 12.7 (69)
Median (range) 55.0 (20.0-90.0)
Left atrial size (cm)
Mean  SD (N) 4.6  0.9 (66)
Median (range) 4.6 (1.9-6.5)
Left atrial thrombus [% (n/N)] 0.0% (0/70)
Criteria for inclusion
History of AF 47.9% (34/71)
CHADS score>2 38.0% (27/71)
Age>75 y 46.5% (33/71)
Hypertension and age>65 y 77.5% (55/71)
Previous stroke 8.5% (6/71)
SD, Standard deviation; NYHA, New York Heart Association; ACE, angiotensin-
converting enzyme; TEE, transesophageal echocardiography; EF, ejection fraction;
AF, atrial fibrillation; CHADS, Congestive Heart Failure, Hypertension, Age> 75
years, Diabetes Mellitus, Stroke.
TABLE 2. Concomitant cardiac operations performed in the
EXCLUDE study
Surgical procedure
Total% (n) (N ¼ 71)
N ¼ 71% (n/N)
CABG 77.5% (55)
Mitral valve 23.9% (17)
Repair 16.9% (12)
Replacement 7.0% (5)
Tricuspid valve 5.6% (4)
Repair 5.6% (4)
Aortic valve 40.8% (29)
Replacement 40.8% (29)
ASD/PFO closure 0.0% (0)
Surgical (ablation or cut-and sew) Maze procedure 35.2% (25)
CABG, Coronary artery bypass grafting; ASD, atrial septal defect; PFO, patent fora-
men ovale.
TABLE 3. Efficacy results as determined by visual assessment and
transesophageal echocardiography intraoperatively and by computed
tomography angiography or transesophageal echocardiography imaging
at 3 months
Efficacy end points % (n/N)
95% 1-sided
Bayesian credible
interval
Procedural success 95.7 (67/70)
by visual assessment 97.1 (68/70)
by TEE 95.7 (67/70)
3-mo success (CT or TEE) 98.4 (60/61) 95–100
By method of assessment
CT evaluation by core laboratory 98.2 (55/56)
TEE evaluation by site 100 (5/5)
Composite end point success
(primary end point)
95.1 (58/61) 90–100
TEE, Transesophageal echocardiography; CT, computed tomography.
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dure, and Maze procedure.
Intraoperative Exclusion
One patient’s LAAwas too small and did not meet eligi-
bility criteria intraoperatively. The remaining 70 patients allThe Journal of Thoracic and Carhad LAA exclusion with the AtriClip device (Figure 1).
There were no instances of damage to the appendage, cir-
cumflex artery, or pulmonary artery intraoperatively in
any patient. Specifically, no patient had bleeding from the
appendage and no additional repair sutures were required
in any patient. Moreover, once deployed, the device did
not migrate intraoperatively, nor was the clip or LAA re-
moved in any patient. Intraoperatively, 67 of 70 patients
(95.7%) had successful exclusion of their appendage as as-
sessed by postoperative TEE (Table 3). Despite successful
visual exclusion of the LAA at the base (Figure 2, A and
B), a residual small stump of the appendage was apparent
by TEE in these 3 patients.Follow-up
Follow-up for all patients is shown in Figure 1. Two pa-
tients did not return for their 1-month visit. At 1-month
follow-up, 68 patients were available for examination
in the clinic. No patient had any clinical evidence ofdiovascular Surgery c Volume 142, Number 5 1005
FIGURE 2. Intraoperative TEE demonstrating (A) patent LAA before AtriClip (Atricure Inc, Westchester, Ohio) device placement (red arrow) and
(B) echocardiographic evidence of LAA exclusion after clip placement (orange arrow; yellow arrowheads indicate pulmonary veins).
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tients withdrew from the study after their 1-month visit and
did not return for follow-up imaging. At 3 months, the re-
maining 66 patients were evaluated. A total of 57 of these re-
maining patients underwent CTA per the study protocol. In 1
of these patients, the CTA images were not obtained using
the appropriate protocol and the patency of the LAAwas un-
able to be evaluated. The remaining patients were not eligible
for CTA because of elevated creatinine per individual site’s
protocol for administration of intravenous contrast agent.
These 9 patients were all offered TEE, 4 of whom refused.
Thus, a total of 61 patients were evaluated with imaging
at 3 months: CTA in 56 and TEE in 5. Of these 61 patients,
all but 1 (98.3%) showed evidence of complete exclusion of
their LAA (Figure 3, A and B). Of the 3 patients who did not
have successful LAA exclusion by TEE at the time of
procedure, only 1 remained unsuccessfully excluded at
the 3-month imaging evaluation. The primary efficacy end
point of composite intraprocedural exclusion by TEE and
exclusion by CTA or TEE at 3 months was 95.1% (58/61)
(Table 3).FIGURE 3. CT scan (A) preoperatively demonstrating patent LAAwith contr
insertion demonstrating endovascular exclusion of the LAA.
1006 The Journal of Thoracic and Cardiovascular SurA total of 66 patients and 64 patients were available at 6
and 12 months for clinical assessment, respectively. There
were no AEs related to the clip (Table 4). The most common
events included postoperative hemorrhage, pleural effusion,
heart block, and congestive heart failure. No event was
thought to be due to the AtriClip device or LAA closure.
At 6-month follow-up, there were no strokes or cardioem-
bolic events. However, at 12-month follow-up, 2 (3.1%)
of the available 64 patients had sustained a neurologic
event. One patient had a transient ischemic attack with
blurry vision that was attributed to a hypertensive crisis,
and 1 patient had developed a clinical stroke of the anterior
circulation that was attributed to cholesterol plaque. At
12-month follow-up, 19 patients (29.7%) remained on
chronic anticoagulation with warfarin.
DISCUSSION
Exclusion of the LAA has become the focus of a diverse
number of novel devices. We report the results of the first
epicardially placed device specifically designed to exclude
blood flow into the LAA. In this FDA-Investigationalast filling lumen and (B) postoperatively at 3 months after AtriClip device
gery c November 2011
TABLE 4. Selected adjudicated adverse events after left atrial
appendage exclusion with the AtriClip device (Atricure Inc,
West Chester, Ohio)
Adverse event name
% (n/N) of patients
with event
<30 d
% (n/N) of patients
with event
<6 mo
AF 2.9 (2/70) 2.9 (2/70)
Atrioventricular block
complete
10.0 (7/70) 10.0 (7/70)
Cardiac failure congestive 4.3 (3/70) 5.7 (4/70)
Gastrointestinal hemorrhage 1.4 (1/70) 2.9 (2/70)
Incision site infection 1.4 (1/70) 1.4 (1/70)
Pneumonia 1.4 (1/70) 1.4 (1/70)
Operative hemorrhage 4.3 (3/70) 4.3 (3/70)
Postprocedural hemorrhage 5.7 (4/70) 5.7 (4/70)
Ejection fraction decreased 0.0 (0/70) 2.9 (2/70)
Renal failure 4.3 (3/70) 5.7 (4/70)
Pleural effusion 7.1 (5/70) 8.6 (6/70)
Pulmonary embolism 1.4 (1/70) 1.4 (1/70)
Respiratory failure 8.6 (6/70) 8.6 (6/70)
Aortic dissection 1.4 (1/70) 1.4 (1/70)
Deep vein thrombosis 1.4 (1/70) 1.4 (1/70)
Hypotension 2.9 (2/70) 2.9 (2/70)
Device-related serious AE 0.0 (0/70) 0.0 (0/70)
Clip placement procedure-
related serious AE
0.0 (0/70) 0.0 (0/70)
No events were attributable to LAA exclusion or the device. AF, Atrial fibrillation;
AE, adverse event.
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United States, there were no significant AEs related to the
device. Moreover, at 3-month imaging follow-up, 98.4%
of patients had complete exclusion of their LAA by CTA
or TEE. It is important to note the 2 late neurologic events
in these patients. Both of these were attributed by the source
reports to hypertensive strokes, but a cardioembolic source
cannot be ruled out entirely. On the basis of these findings,
the AtriClip device demonstrates the safety and efficacy of
LAA occlusion in the short-term and has been approved for
use in patients to exclude the LAA during concomitant car-
diac surgery. This is the first such device designed specifi-
cally for the LAA that is now available in the United States.
The most devastating complication from AF is stroke.
It has been estimated that 20% to 30% of strokes are attrib-
utable to embolic events that develop as a consequence of
AF.Moreover, current anticoagulation strategies carry ama-
jor risk of bleeding of 2.3% and intracranial hemorrhage
risk of 0.9% yearly.12 Because an estimated 90% of throm-
boembolic events in patients with AF are thought to origi-
nate in the LAA, methods to exclude or remove the
appendage might mitigate this risk without the dangers of
anticoagulation.
Before recent novel approaches, surgical LAA exclusion
involved suture ligation or staple excision. Both of these
existing methods can result in incomplete exclusion inThe Journal of Thoracic and Car33% to 55% of cases.5,6 One retrospective study from the
Cleveland Clinic of 137 patients reported successful LAA
closure in 73%, 23%, and 0% of patients who underwent
surgical excision and closure, suture ligation, and staple
exclusion, respectively.6 It has also been suggested that us-
ing a cutting stapler or cutting part of the remnant LAA off
after staple removal may decrease the rate of patency or
flow into the LAA. The Left Atrial Appendage Occlusion
Study randomized patients undergoing CABG to LAA oc-
clusion or control. Although the study was small, stapled
exclusion resulted in 72% exclusion compared with 45%
with suture ligation (P¼ .14).13 Studies suggest that leaving
a persistent communication with the LAA may have the
highest rates of LAA thrombus and can result in the greatest
risk of embolism.6,14,15 Specifically, 41% of patients with
a patent LAA despite attempted surgical closure had
documented thrombus in the LAA.6
Equally concerning to many surgeons is the danger in
managing the frequently fragile LAA. In the Left Atrial
Appendage Occlusion Study trial, 20% of patients who
had their LAA excluded required additional suture repair
for bleeding.13 Gillinov and colleagues16 reported using
a buttressed cutting stapler in 222 patients and documented
a 10% rate of bleeding below the suture line requiring ad-
ditional suture repair. These results have led to trepidation
by many surgeons to remove the LAA.
A number of other epicardial and endocardial devices are
in various stages of development. The Embolic Protection
in Patients With Atrial Fibrillation (PROTECT AF) ran-
domized patients with AF and CHADS2 1 or more to clo-
sure using the Watchman device (Atritech, Inc, Plymouth,
Minn) against warfarin. This device has not been approved
because of the risk of complications, including pericardial
effusion and periprocedural stroke, although it did demon-
strate noninferiority compared with warfarin for risk of
stroke, cardiovascular death, or other embolism.17 Another
percutaneous placed device via a transseptal approach, the
PLAATO (Appriva Medical Inc, Sunnyvale, Calif), has
demonstrated good early results.18 Another percutaneous
device, delivered via a subxiphoid epicardial approach,
has been used successfully in a dog model. The LAA is
identified on the basis of electrical activity, and a suture
lasso is fluoroscopically placed around the LAA.7 Another
device using a lasso and a percutaneous contrast-filled
balloon to identify the LAA (Lariat device) has been docu-
mented in humans.19,20
Preclinical studies with the AtriClip device have docu-
mented complete LAA exclusion by magnetic resonance
imaging and histologic evidence of endothelial formation
on the occluded orifice of the LAA.9,10 Salzberg and
colleagues11 reported the initial European study of 34 pa-
tients that documented no device-related perioperative
complications and stable clip placement by CT imaging at
3 months. These results have led to European CE Markdiovascular Surgery c Volume 142, Number 5 1007
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suggested as a sole therapy for patients with AF to minimize
stroke risk.8 There is evidence to suggest that the AtriClip
device results in electrical isolation, and the device
has been used as an isolated therapy for focal atrial
tachycardia.21
Although the device studied is third generation, the
deployment tool was a first-generation instrument. This re-
usable large deployment tool was cumbersome and can be
used only via a sternotomy. There are 2 currently approved
deployment tools. One is designed for open sternotomy, and
the other is used for thoracoscopic approach. Both are
smaller and more flexible, and have a lower profile than
the deployment tool used in this report.
Limitations
This study is limited in the short-term imaging follow-up
of only 3 months, although clinical follow-up extends to 12
months. This is a relatively small cohort of patients. Longer
follow-up is needed to evaluate for evidence of device mi-
gration. This study was not designed to assess reduction
in stroke risk. Late neurologic events developed in 2 pa-
tients, which did not appear to be related to the LAA to
the best of our knowledge. A significantly larger random-
ized study would be required with longer-term follow-up
to document any efficacy in stroke prophylaxis.
CONCLUSIONS
This multicenter initial trial suggests that exclusion of the
LAA can be performed safely and without injury to the
heart or surrounding structures during open cardiac surgery
with the AtriClip device. In short-term follow-up, there is
evidence of persistent LAA closure with no communication
to the appendage. Long-term studies should be performed to
evaluate the efficacy in the prevention of stroke and rule out
the potential for device migration.
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Dr Bryan Meyers (St Louis, Mo). There was a long list of in-
clusion and exclusion criteria. How restrictive was this trial and
how representative is this patient population compared with the
group of patients you encounter every day in your cardiac surgery
practice?
Dr Ailawadi. On the basis of the exclusion criteria from this
study, I would say approximately half of the patients I see in daily
practice could have qualified for this. The most liberal of the inclu-
sion criteria was age greater than 65 years and hypertension. So
many of the patients we treat meet that criteria in this trial.
Dr Wiley Nifong (Greenville, NC). Great study, great results.
We have been very happy using the clip clinically as well. I didgery c November 2011
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fires. Of course, while you are using it, you can get it down seated
well. It appears, in the beating heart, to guide itself down. After it
fires, I assume you could just use a wire cutter? You could remove
it if you placed it and noticed it was not seated correctly, is that
correct?
Dr Ailawadi. There are a couple of points to mention about de-
ploying the device. The deployment device we used in this study
was a large metal reusable tool, with a manual release. Once you
release it, it is difficult, but it can be removed. You do not need
a wire cutter, but you essentially take 2 pick-ups, separate the
clip, and pull it off and then reattach it to the deployment tool
and put it on again. The current FDA-approved device has a mech-
anism to open and close, and once you are happy with positioning,
then you go ahead and cut the 4 sutures. So the current deployment
device allows repositioning until it is in optimal position.
Dr Azhar Hossain (Indianapolis, Ind). How do you determine
that you have been successful in excluding the entire appendage?
As you know, there is residual appendage left, and the risk of
thrombosis is still present. So are you using TEE assistance during
the procedure?The Journal of Thoracic and CarDr Ailawadi. It certainly can be done. I can tell you that during
a sternotomy when you have the heart lifted up, it can be challeng-
ing to visualize by TEE. So in this situation, clip placement is by
visual inspection. We do use TEE routinely in all of our cases. I
have also performed this multiple times via a minimally invasive
approach when performing a hybrid AF procedure or thoraco-
scopic AF procedure. In this situation, the heart is in its native po-
sition, and we can visualize by TEE before we deploy the clip.
Dr Bryan Meyers (St Louis, Mo). So you showed efficacy
in the ability to exclude the appendage. The next step is going
to be to show clinical effectiveness, and you are going to need
a huge trial, aren’t you, for the rare events you are trying to
prevent?
Dr Ailawadi. Correct.
Dr Meyers. Any idea of where that is going next?
Dr Ailawadi. This is the million dollar question. I suspect it
will require a large trial of at least 2000 patients. We will need to
see what type of funding is available for this type of study. Ul-
timately, this will be required, not just with this particular device
but with all the devices to see the clinical effectiveness of stroke
reduction.diovascular Surgery c Volume 142, Number 5 1009
TABLE E1. Inclusion and exclusion criteria for the EXCLUDE trial
Inclusion criteria
1. Subject is aged  18 years
2. Subject has any 1 of the following risk factors and is thought to benefit
from LAA exclusion
 CHADS score>2
 Age>75 y
 Hypertension and age>65 y
 History of AF (any classification)
 Previous stroke
3. Subject is scheduled to undergo elective non-endoscopic cardiac
surgical procedure(s) including cardiac surgery for  1 of the
following: mitral valve repair or replacement, aortic valve repair or
replacement, tricuspid valve repair or replacement, coronary artery
bypass procedures, concomitant surgical (ablation or cut-and-sew)
Maze procedure, patent foramen ovale closure, or atrial septal defect
repair with the device deployed while on or prepared for
cardiopulmonary bypass support
4. Subject is willing and able to provide written informed consent
5. Subject has a life expectancy of at least 2 y
6. Subject is willing and able to return for scheduled follow-up visits
Exclusion criteria
1. Previous cardiac surgery
2. Thrombus in the LAA/LA that cannot be evacuated before placement
of the AtriClip device
3. Patients requiring surgery other than CABG, cardiac valve surgery,
surgical Maze procedure (ablation or cut-and-sew), PFO closure, or
ASD repair
4. NYHA class IV heart failure symptoms
5. Need for emergency cardiac surgery (ie, cardiogenic shock)
6. Creatinine>200 mmol/L
7. LAA is not appropriate for exclusion based on intraoperative
evaluations.
8. Current diagnosis of active systemic infection
9. Renal failure requiring dialysis or hepatic failure
10. A known drug or alcohol addiction
11.Mental impairment or other conditions that may not allow the subject
to understand the nature, significance, and scope of the study
12. Pregnancy or desire to get pregnant within 12 mo of the study
treatment
13. Preoperative need for intraaortic balloon pump or intravenous
inotropes
14. Patients who have been treated with thoracic radiation
15. Patients in current chemotherapy
16. Patients on long-term treatment with oral or injected steroids (not
including intermittent use of inhaled steroids for respiratory diseases)
17. Patients with known connective tissue disorders
LAA, Left atrial appendage; CHADS, Congestive Heart Failure, Hypertension,
Age> 75 Years, Diabetes Mellitus, Stroke; AF, atrial fibrillation; LA, left atrial;
CABG, coronary artery bypass grafting; ASD, atrial septal defect; PFO, patent fora-
men ovale; NYHA, New York Heart Association.
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